Polyendocrine Metabolic Ovarian SyndromeNCT07822360
Prevalence of Polyendocrine Metabolic Ovarian Syndrome in Patients Diagnosed With Acne Vulgaris in Sohag University Hospital
An observational study of Polyendocrine Metabolic Ovarian Syndrome and Acne Vulgaris, run by Sohag University at 1 site in Egypt.
Trial summary
The aim of this study is to determine the prevalence of polyendocrine metabolic ovarian syndrome (PMOS) among female patients diagnosed with acne vulgaris in Sohag university hospital Read more about this study
- Who is it for?
- Ages 15 to 49 years, women only
- Conditions the study is for
- Polyendocrine Metabolic Ovarian Syndrome, Acne Vulgaris
- How many people
- 90 participants
- Where
- 1 siteEgypt
- Study dates
- 9 Aug 2026to May 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 to 49 years
- Women only
- No healthy volunteers
- Child, Adult
Study population: Female patients diagnosed with acne vulgaris
Who may be able to join
- Female patients at childbearing age ( 15 - 49 years) (World Health, 2024).
- Patients clinically diagnosed with acne vulgaris.
- Clinical diagnosis of Acne vulgaris:
- o Presence of comedones (open/black and closed/white), inflammatory lesions (papules, pustules, or nodules), with or without post-acne changes such as hyperpigmentation or scarring (Oge et al., 2019).
- Patients diagnosed with polyendocrine metabolic ovarian syndrome (PMOS) according to the 2023 International Evidence-based Guideline for PCOS diagnosis.
- Diagnostic criteria for PMOS diagnosis in adults : (Forslund et al., 2024).
Show all 14Show fewer
- Diagnosis of PMOS will be based on the presence of at least two of the following three criteria after exclusion of other etiologies:
- 1. Ovulatory dysfunction:
- Irregular menstrual cycles or oligo/anovulation. 2. Clinical and/or biochemical hyperandrogenism:
- Clinical signs such as hirsutism and/or acne, or biochemical evidence of elevated androgen levels.
- 3. Polycystic ovarian morphology (PCOM):
- Polycystic ovaries detected by pelvic ultrasound, or elevated anti-Müllerian hormone (AMH) level in adults as an alternative to ultrasound.
- Most women with PMOS have a combination of hyperandrogenism and irregular cycles, and in these cases there is no need to assess PCOM. In adolescents, both ovulatory dysfunction and hyperandrogenism are mandatory (Forslund et al., 2024).
- Patients willing to participate and provide informed consent.
Who cannot join
- Pregnant women.
- Lactating mothers
- Women diagnosed with other acneiform lesions
- Women on certain drug treatments like oral contraceptive pills, ovarian stimulating drugs and oral hypoglycemic agents like metformin.
- Patients with incomplete clinical data or who refuse to participate in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Sohag university hospital
Sohag, 82511
Omar Shazly Saleh, Resident, +201004861933, oshazly399@gmail.com
About this study
The aim of this study is to determine the prevalence of polyendocrine metabolic ovarian syndrome (PMOS) among female patients diagnosed with acne vulgaris in Sohag university hospital
Read the detailed description
A cross-sectional observational study designed to determine the prevalence of polycystic ovary syndrome (PCOS) among patients diagnosed with acne vulgaris attending Sohag University Hospital.
- Keywords
- Polyendocrine metabolic ovarian syndrome, Acne vulgaris, PMOS
- Medical subject headings
- Acne Vulgaris
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients diagnosed with acne vulgaris | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Prevalence of polyendocrine metabolic ovarian syndrome (PMOS) among patients diagnosed with acne vulgaris in Sohag university hospital
Measured: Over 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Sep 2026
- Study start9 Aug 2026
- Primary completion8 Feb 2027 (estimated)
- Study completionMay 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (20)Papers the sponsor has linked to this study.
- Other trials for Polyendocrine Metabolic Ovarian SyndromeStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Omar Shazly Saleh, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07822360
- Sponsor's protocol ID
- Soh-Med-26-8-8MS
- Status last verified
- Sep 2026
- First submitted
- 10 Sep 2026
- Last updated
- 16 Sep 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Zhuang C, Luo X, Wang W, Sun R, Qi M, Yu J. Cardiovascular Risk According to Body Mass Index in Women of Reproductive Age With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2022 Feb 16;9:822079. doi: 10.3389/fcvm.2022.822079. eCollection 2022.
PubMed 35252398Vasam M, Korutla S, Bohara RA. Acne vulgaris: A review of the pathophysiology, treatment, and recent nanotechnology based advances. Biochem Biophys Rep. 2023 Nov 23;36:101578. doi: 10.1016/j.bbrep.2023.101578. eCollection 2023 Dec.
PubMed 38076662Teede HJ, Khomami MB, Morman R, Laven JSE, Joham AE, Costello MF, Patil M, Rees DA, Berry L, Cree MG, Zhao H, Norman RJ, Dokras A, Piltonen T; Global Name Change Consortium. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026 Jun 6;407(10545):2329-2339. doi: 10.1016/S0140-6736(26)00717-8. Epub 2026 May 12.
PubMed 42119588Taieb A, Feryel A. Deciphering the Role of Androgen in the Dermatologic Manifestations of Polycystic Ovary Syndrome Patients: A State-of-the-Art Review. Diagnostics (Basel). 2024 Nov 16;14(22):2578. doi: 10.3390/diagnostics14222578.
PubMed 39594244Stener-Victorin E, Teede H, Norman RJ, Legro R, Goodarzi MO, Dokras A, Laven J, Hoeger K, Piltonen TT. Polycystic ovary syndrome. Nat Rev Dis Primers. 2024 Apr 18;10(1):27. doi: 10.1038/s41572-024-00511-3.
PubMed 38637590Ruth KS, Day FR, Tyrrell J, Thompson DJ, Wood AR, Mahajan A, Beaumont RN, Wittemans L, Martin S, Busch AS, Erzurumluoglu AM, Hollis B, O'Mara TA; Endometrial Cancer Association Consortium; McCarthy MI, Langenberg C, Easton DF, Wareham NJ, Burgess S, Murray A, Ong KK, Frayling TM, Perry JRB. Using human genetics to understand the disease impacts of testosterone in men and women. Nat Med. 2020 Feb;26(2):252-258. doi: 10.1038/s41591-020-0751-5. Epub 2020 Feb 10.
PubMed 32042192Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. Gastroenterol Hepatol Bed Bench. 2013 Winter;6(1):14-7.
PubMed 24834239Pakornphadungsit K, Harnchoowong S, Wattanakrai P. Evaluation of an Acne Severity Grading Self-Assessment System Suitable for the Thai Population - A Pilot Study. Clin Cosmet Investig Dermatol. 2023 Nov 3;16:3171-3179. doi: 10.2147/CCID.S427648. eCollection 2023.
PubMed 37941850Ollila MM, Hoek A, Piltonen TT. The association between polycystic ovary syndrome and early cardiovascular disease morbidity strengthens. Eur J Endocrinol. 2023 Jul 20;189(1):R4-R5. doi: 10.1093/ejendo/lvad083. No abstract available.
PubMed 37461221Oge' LK, Broussard A, Marshall MD. Acne Vulgaris: Diagnosis and Treatment. Am Fam Physician. 2019 Oct 15;100(8):475-484.
PubMed 31613567Liu Q, Tang B, Zhu Z, Kraft P, Deng Q, Stener-Victorin E, Jiang X. A genome-wide cross-trait analysis identifies shared loci and causal relationships of type 2 diabetes and glycaemic traits with polycystic ovary syndrome. Diabetologia. 2022 Sep;65(9):1483-1494. doi: 10.1007/s00125-022-05746-x. Epub 2022 Jun 30.
PubMed 35771237Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, Challenges, and Guiding Treatment. J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1071-e1083. doi: 10.1210/clinem/dgaa839.
PubMed 33211867Hazarika N. Acne vulgaris: new evidence in pathogenesis and future modalities of treatment. J Dermatolog Treat. 2021 May;32(3):277-285. doi: 10.1080/09546634.2019.1654075. Epub 2019 Aug 29.
PubMed 31393195Forslund M, Melin J, Stener-Victorin E, Hirschberg AL, Teede H, Vanky E, Piltonen T. International evidence-based guideline on assessment and management of PCOS-A Nordic perspective. Acta Obstet Gynecol Scand. 2024 Jan;103(1):7-12. doi: 10.1111/aogs.14725. Epub 2023 Nov 20.
PubMed 37983875Doshi A, Zaheer A, Stiller MJ. A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol. 1997 Jun;36(6):416-8. doi: 10.1046/j.1365-4362.1997.00099.x. No abstract available.
PubMed 9248884
Study at a glance
From the registry record, last updated by the sponsor on 16 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prevalence of Polyendocrine Metabolic Ovarian Syndrome in Patients Diagnosed With Acne Vulgaris in Sohag University Hospital
- ClinicalTrials.gov ID
- NCT07822360
- Acronym / sponsor ID
- Soh-Med-26-8-8MS
- Keywords
- Polyendocrine metabolic ovarian syndrome, Acne vulgaris, PMOS
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 9 Aug 2026 (actual)
- Primary completion
- 8 Feb 2027 (estimated)
- Study completion
- May 2027 (estimated)
- First posted
- 16 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to determine the prevalence of polyendocrine metabolic ovarian syndrome (PMOS) among female patients diagnosed with acne vulgaris in Sohag university hospital
Detailed description
A cross-sectional observational study designed to determine the prevalence of polycystic ovary syndrome (PCOS) among patients diagnosed with acne vulgaris attending Sohag University Hospital.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients diagnosed with acne vulgaris | – | – |
Who may qualify
- Ages
- 15 to 49 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Female patients diagnosed with acne vulgaris
Key inclusion criteria (14 listed)
- Female patients at childbearing age ( 15 - 49 years) (World Health, 2024).
- Patients clinically diagnosed with acne vulgaris.
- o Presence of comedones (open/black and closed/white), inflammatory lesions (papules, pustules, or nodules), with or without post-acne changes such as hyperpigmentation or scarring (Oge et al., 2019).
- Patients diagnosed with polyendocrine metabolic ovarian syndrome (PMOS) according to the 2023 International Evidence-based Guideline for PCOS diagnosis.
- Diagnostic criteria for PMOS diagnosis in adults : (Forslund et al., 2024).
Key exclusion criteria (5 listed)
- Pregnant women.
- Lactating mothers
- Women diagnosed with other acneiform lesions
- Women on certain drug treatments like oral contraceptive pills, ovarian stimulating drugs and oral hypoglycemic agents like metformin.
- Patients with incomplete clinical data or who refuse to participate in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Prevalence of polyendocrine metabolic ovarian syndrome (PMOS) among patients diagnosed with acne vulgaris in Sohag university hospital
Time frame: Over 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Sep 2026.
- Background: PubMed 35252398Zhuang C, Luo X, Wang W, Sun R, Qi M, Yu J. Cardiovascular Risk According to Body Mass Index in Women of Reproductive Age With Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis. Front Cardiovasc Med. 2022 Feb 16;9:822079. doi: 10.3389/fcvm.2022.822079. eCollection 2022.
- Background: PubMed 38076662Vasam M, Korutla S, Bohara RA. Acne vulgaris: A review of the pathophysiology, treatment, and recent nanotechnology based advances. Biochem Biophys Rep. 2023 Nov 23;36:101578. doi: 10.1016/j.bbrep.2023.101578. eCollection 2023 Dec.
- Background: PubMed 42119588Teede HJ, Khomami MB, Morman R, Laven JSE, Joham AE, Costello MF, Patil M, Rees DA, Berry L, Cree MG, Zhao H, Norman RJ, Dokras A, Piltonen T; Global Name Change Consortium. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026 Jun 6;407(10545):2329-2339. doi: 10.1016/S0140-6736(26)00717-8. Epub 2026 May 12.
- Background: PubMed 39594244Taieb A, Feryel A. Deciphering the Role of Androgen in the Dermatologic Manifestations of Polycystic Ovary Syndrome Patients: A State-of-the-Art Review. Diagnostics (Basel). 2024 Nov 16;14(22):2578. doi: 10.3390/diagnostics14222578.
- Background: PubMed 38637590Stener-Victorin E, Teede H, Norman RJ, Legro R, Goodarzi MO, Dokras A, Laven J, Hoeger K, Piltonen TT. Polycystic ovary syndrome. Nat Rev Dis Primers. 2024 Apr 18;10(1):27. doi: 10.1038/s41572-024-00511-3.
- Background: PubMed 32042192Ruth KS, Day FR, Tyrrell J, Thompson DJ, Wood AR, Mahajan A, Beaumont RN, Wittemans L, Martin S, Busch AS, Erzurumluoglu AM, Hollis B, O'Mara TA; Endometrial Cancer Association Consortium; McCarthy MI, Langenberg C, Easton DF, Wareham NJ, Burgess S, Murray A, Ong KK, Frayling TM, Perry JRB. Using human genetics to understand the disease impacts of testosterone in men and women. Nat Med. 2020 Feb;26(2):252-258. doi: 10.1038/s41591-020-0751-5. Epub 2020 Feb 10.
- Background: PubMed 24834239Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. Gastroenterol Hepatol Bed Bench. 2013 Winter;6(1):14-7.
- Background: PubMed 37941850Pakornphadungsit K, Harnchoowong S, Wattanakrai P. Evaluation of an Acne Severity Grading Self-Assessment System Suitable for the Thai Population - A Pilot Study. Clin Cosmet Investig Dermatol. 2023 Nov 3;16:3171-3179. doi: 10.2147/CCID.S427648. eCollection 2023.
- Background: PubMed 37461221Ollila MM, Hoek A, Piltonen TT. The association between polycystic ovary syndrome and early cardiovascular disease morbidity strengthens. Eur J Endocrinol. 2023 Jul 20;189(1):R4-R5. doi: 10.1093/ejendo/lvad083. No abstract available.
- Background: PubMed 31613567Oge' LK, Broussard A, Marshall MD. Acne Vulgaris: Diagnosis and Treatment. Am Fam Physician. 2019 Oct 15;100(8):475-484.
- Background: PubMed 35771237Liu Q, Tang B, Zhu Z, Kraft P, Deng Q, Stener-Victorin E, Jiang X. A genome-wide cross-trait analysis identifies shared loci and causal relationships of type 2 diabetes and glycaemic traits with polycystic ovary syndrome. Diabetologia. 2022 Sep;65(9):1483-1494. doi: 10.1007/s00125-022-05746-x. Epub 2022 Jun 30.
- Background: PubMed 33211867Hoeger KM, Dokras A, Piltonen T. Update on PCOS: Consequences, Challenges, and Guiding Treatment. J Clin Endocrinol Metab. 2021 Mar 8;106(3):e1071-e1083. doi: 10.1210/clinem/dgaa839.
- Individual participant dataSharing planned: Undecided
Related trials for Polyendocrine Metabolic Ovarian Syndrome
Not yet recruiting
Time-Restricted Eating as a Dietary Intervention for Polyendocrine Metabolic Ovarian Syndrome (PMOS): Protocol for a Randomized Controlled Trial
Polycystic Ovary Syndrome
Active, not recruiting
Inspiratory Muscle Training for the Management of Polyendocrine Metabolic Ovarian Syndrome
Poly Cystic Ovary Syndrome
Not yet recruitingObservational study
Metabolic and Hormonal Parameters in Women With Polyendocrine Metabolic Ovarian Syndrome
Polycystic Ovary Syndrome, Polycystic Ovary Syndrome (PCOS) Women
Recruiting
Fecal Microbiota Transplantation for Obese Women With Polyendocrine Metabolic Ovarian Syndrome
PCOS (Polycystic Ovary Syndrome)
Enrolling by invitation
Effect of Zinc Supplementation on Insulin Resistance and Clinical Features in Women With Polyendocrine Metabolic Ovarian Syndrome.
Polyendocrine Metabolic Ovarian Syndrome (PMOS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Polyendocrine Metabolic Ovarian Syndrome and Acne Vulgaris, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 16 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Omar Shazly Saleh, Resident (+201004861933, oshazly399@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Prevalence of polyendocrine metabolic ovarian syndrome (PMOS) among patients diagnosed with acne vulgaris in Sohag university hospital (time frame: Over 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07822360, which also lists 20 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Sep 2026.